Merck's Keytruda Combo Trial Meets Overall Survival Endpoint In PD-L1 Expressing Breast Cancer Patients

Loading...
Loading...
  • Merck & Co Inc MRK has announced overall survival (OS) results from Phase 3 KEYNOTE-355 trial evaluating Keytruda (pembrolizumab) in combination with chemotherapy for the treatment of patients with metastatic triple-negative breast cancer (mTNBC).
  • Final analysis show first-line treatment with Keytruda/Chemo combo demonstrated a statistically significant and clinically meaningful improvement in OS compared with chemotherapy alone in patients with mTNBC whose tumors expressed PD-L1. 
  • No new safety signals were identified. 
  • These OS results will be presented at an upcoming medical meeting and submitted to regulatory authorities.
  • The FDA also approved Keytruda - Chemo combo in early-stage triple-negative breast cancer patients at high risk.
  • Price Action: MRK shares are up 0.01% at $77.25 during the premarket session on the last check Tuesday.
Posted In: BiotechNewsHealth CareGeneralbreast cancerBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...